Simbrinza (Brinzolamide/Brimonidine Tart) Patent Expiration, LOE Window & CMS Spending
Simbrinza (Brinzolamide/Brimonidine Tart) by Novartis: FDA Orange Book LOE 2030-10-30, 0 AB generics, $83.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N204251 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2030-10-30 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $83.5M |
| 2024 Medicare Part D Spend | $78.9M |
| 2024 Medicaid Spend | $4.7M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.